Stocktoria
Vir Biotechnology, Inc. VIR
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-10-11
Vir Biotechnology, Inc. financials (annual)
Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $68.6M | $74.2M | $86.2M | $1.6B | $1.1B | $76.4M | $8.1M | $10.7M |
| R&D expense | $456.0M | $506.5M | $579.7M | $474.6M | $448.0M | $302.4M | $148.5M | $100.2M |
| SG&A expense | $92.1M | $119.0M | $174.4M | $161.8M | $160.8M | $70.9M | $37.6M | — |
| Operating income | -$479.3M | -$587.2M | -$684.3M | $833.1M | $420.8M | -$297.0M | -$178.0M | -$118.7M |
| Income tax | $217,000 | -$1.1M | -$13.1M | $238.4M | $21.2M | $54,000 | $154,000 | -$480,000 |
| Net income | -$438.0M | -$522.0M | -$615.1M | $515.8M | $528.6M | -$298.7M | -$174.7M | -$115.9M |
| EPS (diluted) | $-3.16 | $-3.83 | $-4.59 | $3.83 | $3.96 | $-2.51 | $-5.76 | — |
| Operating cash flow | -$391.8M | -$446.4M | -$778.8M | $1.7B | -$47.6M | -$190.9M | -$129.6M | -$94.1M |
| Free cash flow | -$396.6M | -$453.7M | -$800.4M | $1.6B | -$69.4M | -$197.5M | -$138.6M | -$102.3M |
| Cash & equivalents | $232.2M | $222.9M | $241.6M | $848.6M | $347.8M | $436.6M | $109.3M | $47.6M |
| Total assets | $1.0B | $1.4B | $1.9B | $2.8B | $2.0B | $918.8M | $512.1M | $191.6M |
| Total liabilities | $237.5M | $248.4M | $328.8M | $724.1M | $522.4M | $201.9M | $88.1M | $61.6M |
| Shareholders' equity | $765.3M | $1.2B | $1.6B | $2.1B | $1.4B | $716.9M | $423.9M | -$179.2M |
Growth · year-over-year · Revenue CAGR 30.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | -7.6% | -13.9% | -94.7% | +47.5% | +1334.4% | +843.9% | -24.2% | — |
| Net income growth | — | — | -219.2% | -2.4% | — | — | — | — |
| EPS growth | — | — | -219.8% | -3.3% | — | — | — | — |
| Free cash flow growth | — | — | -150.2% | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.